SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sivula A, Ronni-Sivula H. The changing picture of primary hyperparathyroidism in the years 1956-1966. Ann Chir Gynaecol. 1984;73:319324.
  • 2
    Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189193.
  • 3
    Lundgren E, Rastad J, Thurfjell E, et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;294:287294.
  • 4
    Jorde R, Bonaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso Study. J Clin Epidemiol. 2000;53:11641169.
  • 5
    Soreide JA, van Heerden JA, Grant CS, et al. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones. Surgery. 1996;120:10331037.
  • 6
    Silverberg SJ, Bilezikian JP, Bone HG, et al. Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:22752285.
  • 7
    Walgenbach S, Hommel G, Junginger T. Outcome after surgery for primary hyperparathyroidism: ten-year prospective follow-up study. World J Surg. 2000;24:564569.
  • 8
    Eigelberger MS, Clark OH. Surgical approaches to primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2000;29:479502.
  • 9
    NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med. 1991;114:593597.
  • 10
    Bilezikian JP, Potts JT, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;87:53535361.
  • 11
    Bilezikian JP, Khan AA, and Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335339.
  • 12
    Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement and guidelines from the fourth international workshop. J Clin Endocrinol Metab. 2014, In Press.
  • 13
    Clark OH, Wilkes W, Siperstein AE, Duh QY. Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge. J Bone Miner Res. 1991;6:S135S142.
  • 14
    Ronni-Sivula H, Sivula A. Long-term effect of surgical treatment on the symptoms of primary hyperparathyroidism. Ann Clin Res. 1985;17:141147.
  • 15
    Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. Endocr J. 1997;44:367374.
  • 16
    Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513518.
  • 17
    Hasse C, Sitter H, Bachmann S, et al. How asymptomatic is asymptomatic primary hyperparathyroidism? Exp Clin Endocrinol Diabetes. 2000;108:265274.
  • 18
    Purnell DA, Smith LH, Scholz DA, et al. Primary hyperparathyroidism: a prospective clinical study. Am J Med. 1971;50:670678.
  • 19
    Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc. 1981;56:473478.
  • 20
    Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:12491255.
  • 21
    Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:34623470.
  • 22
    Redman C, Bodenner D, Stack B Jr. Role of vitamin D deficiency in continued hyperparathyroidism following parathyroidectomy. Head Neck. 2009;31:11641167.
  • 23
    Grubbs EG, Rafeeq S, Jimenez C, et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery. 2008;144:852858.
  • 24
    Adler JT, Sippel RS, Chen H. 25-Hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol. 2010;17:29582962.
  • 25
    Press D, Politz D, Lopez J, Norman J. The effect of vitamin D levels on postoperative calcium requirements, symptomatic hypocalcemia, and parathormone levels following parathyroidectomy for primary hyperparathyroidism. Surgery. 2011;150:10611068.
  • 26
    Pappu S, Donovan P, Cheng D, Udelsman R. Sestamibi scans are not all created equally. Arch Surg. 2005;140:383386.
  • 27
    Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:351365.
  • 28
    Barczynski M, Golkowski F, Konturek A, et al. Technetium-99m-sestamibi subtraction scintigraphy versus ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clin Endocrinol. 2006;65:106113.
  • 29
    Lo CY, Lang BH, Chan WF, et al. A prospective evaluation of preoperative localization by technetium-99m-sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am J Surg. 2007;193:155159.
  • 30
    Geatti O, Shapiro B, Orsolon PG, et al. Localization of parathyroid enlargement: experience with technetium-99m methoxyisobutylisonitrile and thallium-201 scintigraphy, ultrasonography and computed tomography. Eur J Nucl Med. 1994;21:1722.
  • 31
    Berber E, Parikh RT, Ballem N, et al. Factors contributing to negative parathyroid localization: an analysis of 1000 patients. Surgery. 2008;144:7479.
  • 32
    Johnston LB, Carroll MJ, Britton KE, et al. The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. J Clin Endocrinol Metab.1996:81:346352.
  • 33
    Jones JM, Russell CF, Ferguson WR, Laird JD. Preoperative sestamibi-technitium subtraction scintigraphy in primary hyperparathyroidism: experience with 156 consecutive patients. Clin Radiol. 2001;56:556559.
  • 34
    Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable? Ann Surg. 2005;242:375380; discussion 380-383.
  • 35
    Rodgers SE, Hunter GJ, Hambert LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006;140:932940; discussion 940-941.
  • 36
    Starker L, Mahajan A, Bjorklund P, et al. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2010;18:17231728.
  • 37
    Kettle AG, O'Doherty MJ. Parathyroid imaging: how good is it and how should it be done? Semin Nucl Med. 2006;36:206211.
  • 38
    Mahajan A, Starker LF, Ghita M, et al. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg. 2012;36:13351339.
  • 39
    Carling T, Udelsman R. Minimally invasive parathyroidectomy. In: Oertli D, Udelsman R, eds. Surgery of the Thyroid and Parathyroid Glands. Berlin, Germany: Springer-Verlag; 2012:477479.
  • 40
    Norman J, Politz D. Five thousand parathyroid operations without frozen section of PTH assays: measuring individual parathyroid gland hormone production in real time. Ann Surg Oncol. 2009;16:656666.
  • 41
    Quillo AR, Bumpous JM, Goldstein RE, et al. Minimally invasive parathyroid surgery, the Norman 20% rule: is it valid? Am Surg. 2011;77:484487.
  • 42
    Irvin GL 3rd, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg. 1991;162:299302.
  • 43
    Richards ML, Thompson GB, Farley DR, Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg. 2011;146:280285.
  • 44
    Udelsman R, Donovan P, Shaw C. Cure predictability during parathyroidectomy. World J Surg. 2014;38:525533.
  • 45
    Westra WH, Pritchett DD, Udelsman R. Intraoperative confirmation of parathyroid tissue during parathyroid exploration: a retrospective evaluation of the frozen section. Am J Surg Pathol. 1998;22:538544.
  • 46
    Miccoli P, Materazzi G, Baggiani A, Miccoli M. Mini-invasive video-assisted surgery of the thyroid and parathyroid glands: a 2011 update. J Endocrinol Invest. 2011;34:473480.
  • 47
    Ikeda Y, Takami H, Nimi M, et al. Endoscopic thyroidectomy and parathyroidectomy by the axillary approach. A preliminary report. Surg Endosc. 2002;16:9295.
  • 48
    Choe JH, Kim SW, Chung KW, et al. Endoscopic thyroidectomy using a new bilateral axillo-breast approach. World J Surg. 2007;31:601606.
  • 49
    Koh YW, Kim JW, Lee SW, Choi EC. Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc. 2009;23:20532060.
  • 50
    Lee KE, Kim HY, Park WS, et al. Postauricular and axillary approach endoscopic neck surgery: a new technique. World J Surg. 2009;33:767772.
  • 51
    Landry CS, Grubbs EG, Morris GS, et al. Robot assisted transaxillary surgery (RATS) for the removal of thyroid and parathyroid glands. Surgery. 2011;149:549555.
  • 52
    Karakas E, Steinfeldt T, Gockel A, et al. Transoral thyroid and parathyroid surgery—development of a new transoral technique. Surgery. 2011;150:108115.
  • 53
    Udelsman R, Lin Q, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253:585591.
  • 54
    Foley CS, Agcaoglu O, Siperstein AE, Berber E. Robotic transaxillary endocrine surgery: a comparison with conventional open technique. Surg Endosc. 2012;26:22592266.
  • 55
    Boccara G, Guenoun T, Aidan P. Anesthetic implications for robot-assisted transaxillary thyroid and parathyroid surgery: a report of twenty cases. J Clin Anesth. 2013;25:508512.
  • 56
    Saunders BD, Wainess RM, Dimick JB, et al. Who performs endocrine operations in the United States? Surgery. 2003;134:924931.
  • 57
    Mitchell J, Milas M MD, Barbosa G, et al. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery. 2008;144:899907.
  • 58
    Chen H, Wang TS, Yen TWF, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg. 2010;252:691695.
  • 59
    Malmaeus J, Granberg P-O, Halvorsen J, et al. Parathyroid surgery in Scandinavia. Acta Chir Scand. 1988;154:409413.
  • 60
    Bergenfelz A, Jansson S, Martensson H, et al. Scandinavian quality register for thyroid and parathyroid surgery: audit of surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2007;392:445451.
  • 61
    Slepavicius A, Beisa V, Janusonis V, Strupas K. Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg. 2008;393:659666.
  • 62
    Miccoli P, Berti P, Materazzi G, et al. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: a prospective randomized trial. Surg Endosc. 2008;22:398400.
  • 63
    Aarum S, Nordenstrom J, Reihner E, et al. Operation for primary hyperparathyroidism: the new versus the old order. A randomised controlled trial of preoperative localisation. Scand J Surg. 2007;96:2630.
  • 64
    Sozio A, Schietroma M, Franchi L, et al. Parathyroidectomy: bilateral exploration of the neck versus minimally invasive radioguided treatment. Minerva Chir. 2005;60:8389.
  • 65
    Bergenfelz A, Kanngiesser V, Zielke A, et al. Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005;92:190197.
  • 66
    Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236:543551.
  • 67
    Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007;246:976980.
  • 68
    Miccoli P, Bendinelli C, Berti P, et al. Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: a prospective randomized study. Surgery. 1999;126:11171121.
  • 69
    Starker LF, Bjorklund P, Theoharis C, Long WD 3rd, Carling T, Udelsman R. Clinical and histopathological characteristics of hyperparathyroidism-induced hypercalcemic crisis. World J Surg. 2011;35:331335.
  • 70
    Udelsman R, Donovan PI. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg. 2006;244:471479.
  • 71
    Prescott JD, Udelsman R. Remedial operation for primary hyperparathyroidism. World J Surg. 2009;33:23242334.
  • 72
    Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. J Clin Endocrinol Metab. 2011;96:29502958.
  • 73
    Hessman O, Stalberg P, Sundin A, et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg. 2008;32:774781.
  • 74
    Starker LF, Akerstrom T, Song WD, et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012;3:4451.
  • 75
    Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998;62:232244.
  • 76
    Kulke MG, Benson AB, Bergsland E, et al. Neuroendocrine tumors. In: NCCN Oncology Clinical Practice Guidelines in Oncology (NCCN Guidelines), v.2.2013. Fort Washington, PA: NCCN; 2013. Available at: www.nccn.org./professionals/physician_gls/PDF/neuroendocrine.pdf. Accessed September 30, 2013.
  • 77
    Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124:993999.
  • 78
    Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003;134:858864; discussion 864-855.
  • 79
    Kivlen MH, Bartlett DL, Libutti SK, et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery. 2001;130:991998.
  • 80
    Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005;140:374382.
  • 81
    Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:15751579.
  • 82
    Skinner MA, Norton JA, Moley JF, et al. Heterotopic autotransplantation of parathyroid tissue in children undergoing total thyroidectomy. J Pediatr Surg. 1997;32:510513.
  • 83
    Kouvaraki M, Perrier N, Shapiro S, et al. Surgical treatment of multiple endocrine neoplasia type 2 (MEN-2). In: Pollock R, Curley S, Ross M, et al, eds. Advanced Therapy in Surgical Oncology. Hamilton, ON: BC Decker Inc.; 2008:465473.
  • 84
    Wassif WS, Moniz CR, Friedman E, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab. 1993;77:14851489.
  • 85
    Haven CJ, Wong FK, Van Dam EW, et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2000;85:14491454.
  • 86
    Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676680.
  • 87
    Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine. 2002;81:126.
  • 88
    Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004;41:155160.
  • 89
    Cetani F, Pardi E, Ambrogini E, et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol. 2006;64:146152.
  • 90
    Cole DE, Janicic N, Salisbury SR, Hendy GN. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. Am J Med Genet. 1997;71:202210.
  • 91
    Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab. 2000;85:20422047.
  • 92
    Scabo E, Carling T, Hessman O, Rastad J. Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab. 2002;87:39613965.
  • 93
    Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of bisphosphonate and caclimimetic in neonatal severe primary hyperparathyroidism. Pediatrics. 2012;129:e812e816.
  • 94
    Waller S, Kurzawinski T, Spitz L, et al. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr. 2004;163:589594.
  • 95
    Matsuoka S, Tominaga Y, Sato T, et al. Recurrent renal hyperparathyroidism caused by parathyromatosis. World J Surg. 2007;31:299305.
  • 96
    Tublin ME, Yim JH, Carty SE. Recurrent hyperparathyroidism secondary to parathyromatosis: clinical and imaging findings. J Ultrasound Med. 2007;26:847851.
  • 97
    Shen WT. Parathyromatosis and parathyroid cancer. Cancer Treat Res. 2010;153;105116.
  • 98
    Hundahl SA, Fleming ID, Fremgen AM, Mench HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538544.
  • 99
    Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:17221729.
  • 100
    Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine. 1992;71:197205.
  • 101
    Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004;100:900905.